Krystal Biotech's (KRYS) "Buy" Rating Reaffirmed at HC Wainwright

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $200.00 price objective on the stock. HC Wainwright's price target points to a potential upside of 27.19% from the company's previous close.

A number of other research firms have also recently commented on KRYS. Guggenheim increased their target price on Krystal Biotech from $130.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, February 27th. William Blair restated an "outperform" rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Stifel Nicolaus restated a "buy" rating and set a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Finally, Citigroup increased their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $171.00.

Krystal Biotech Trading Down 0.8 %

Shares of Krystal Biotech stock traded down $1.28 during trading on Monday, hitting $157.25. The stock had a trading volume of 341,796 shares, compared to its average volume of 371,384. The firm has a market cap of $4.48 billion, a price-to-earnings ratio of 1,999.00 and a beta of 0.85. Krystal Biotech has a 12 month low of $82.09 and a 12 month high of $189.97. The business's 50-day moving average is $159.74 and its 200 day moving average is $130.32.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.82. The firm had revenue of $42.14 million during the quarter, compared to the consensus estimate of $27.43 million. During the same period in the previous year, the company posted ($1.25) EPS. As a group, equities analysts expect that Krystal Biotech will post 1.89 EPS for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 5,000 shares of the firm's stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the sale, the chief accounting officer now directly owns 12,936 shares in the company, valued at $2,145,823.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares of the company's stock, valued at $265,138,786.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Kathryn Romano sold 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares of the company's stock, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. Insiders sold 38,087 shares of company stock worth $6,210,591 over the last three months. Company insiders own 14.10% of the company's stock.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the company. Commonwealth Equity Services LLC boosted its stake in shares of Krystal Biotech by 2.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 4,426 shares of the company's stock worth $513,000 after acquiring an additional 110 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Krystal Biotech by 10.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,007 shares of the company's stock worth $349,000 after acquiring an additional 283 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Krystal Biotech by 2.8% during the 3rd quarter. Deutsche Bank AG now owns 13,499 shares of the company's stock worth $1,566,000 after acquiring an additional 365 shares during the last quarter. EAM Investors LLC boosted its stake in shares of Krystal Biotech by 2.4% during the 3rd quarter. EAM Investors LLC now owns 16,091 shares of the company's stock worth $1,867,000 after acquiring an additional 377 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Krystal Biotech by 111.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company's stock worth $83,000 after acquiring an additional 379 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).